Suramin

Generic Name: Suramin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₅₁H_₄₀N_₆O_₂₃S_₆

CAS Number: 145-63-1

Unique Ingredient Identifier: 6032D45BEM

Background: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties. Suramin is manufactured by Bayer in Germany as Germanin®.

Indication: For treatment of human sleeping sickness, onchocerciasis and other diseases caused by trypanosomes and worms.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Study of Suramin in Subjects With Furosemide-Resistant AKI

Phase 2

Active, not recruiting

Conditions: Acute Kidney Injury

Interventions: Drug: Placebo
Drug: Suramin

First Posted Date: 2020-08-03

Last Posted Date: 2023-05-03

Lead Sponsor: Rediscovery Life Sciences

Target Recruit Count: 68

Registration Number: NCT04496596

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Baylor Scott and White Research Institute - Dallas Clinical Trials Office, Dallas, Texas, United States

and more 9 locations

University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial

Phase 1

Completed

Conditions: Autism Spectrum Disorders

Interventions: Drug: Saline
Drug: Suramin

First Posted Date: 2015-07-24

Last Posted Date: 2019-07-16

Lead Sponsor: University of California, San Diego

Target Recruit Count: 10

Registration Number: NCT02508259

Locations: 🇺🇸
University of California, San Diego School of Medicine, La Jolla, California, United States

Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Carcinoma, Non Small Cell Lung

Interventions: Drug: Docetaxel
Drug: Suramin

First Posted Date: 2012-08-23

Last Posted Date: 2020-05-12

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 80

Registration Number: NCT01671332

Locations: 🇺🇸
University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Flutamide, Suramin, and Hydrocortisone in Treating Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

First Posted Date: 2004-08-24

Last Posted Date: 2010-11-09

Lead Sponsor: Eastern Cooperative Oncology Group

Registration Number: NCT00002881

Locations: 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States

S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery

Phase 2

Terminated

Conditions: Adrenocortical Carcinoma

Interventions: Drug: suramin
Drug: therapeutic hydrocortisone

First Posted Date: 2004-07-30

Last Posted Date: 2012-10-05

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 13

Registration Number: NCT00002921

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Louisiana State University Hospital - Shreveport, Shreveport, Louisiana, United States

and more 62 locations

Suramin in Treating Patients With Recurrent Primary Brain Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-05-26

Last Posted Date: 2013-06-21

Lead Sponsor: Emory University

Registration Number: NCT00002639

Locations: 🇺🇸
Department of Neurosurgery - Emory, Atlanta, Georgia, United States

Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2004-05-20

Last Posted Date: 2012-05-03

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 54

Registration Number: NCT00004073

Locations: 🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

and more 6 locations

Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer

Phase 1

Completed

Conditions: Stage IV Renal Cell Cancer
Recurrent Renal Cell Carcinoma

Interventions: Drug: Fluorouracil
Other: Pharmacological Study
Drug: Suramin

First Posted Date: 2004-05-17

Last Posted Date: 2015-05-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00083109

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Adrenocortical Carcinoma
Breast Cancer
Colorectal Cancer
Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-04-30

Last Posted Date: 2011-08-03

Lead Sponsor: Mayo Clinic

Registration Number: NCT00003038

Locations: 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States

Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

Phase 2

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-03-01

Last Posted Date: 2013-02-04

Lead Sponsor: University of Arkansas

Registration Number: NCT00002652

Locations: 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy